Today it was reported that the CFO & Treasurer of SAGE Therapeutics (SAGE), Kimi Iguchi, exercised options to buy 4,723 SAGE shares at $0.45 a share, for a total transaction value of $2,125.
This recent transaction increases Kimi Iguchi’s holding in the company by 334.25% to a total of $926K.
See today’s analyst top recommended stocks >>
Based on SAGE Therapeutics’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $273K and GAAP net loss of $158 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $69.42 million. Currently, SAGE Therapeutics has an average volume of 360.9K. The Company has a Price to Book ratio of 8.1995.
Based on 11 analyst ratings, the analyst consensus is Strong Buy with an average price target of $195.30, reflecting a 25.5% upside. 10 different firms, including BMO Capital and Cowen & Co., currently also have a Buy rating on the stock. Starting in January 2019, SAGE received 9 Buy ratings in a row.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.